Document Detail


An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.
MedLine Citation:
PMID:  11303007     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Omega-3 fatty acids, such as those present in fish oil, have been reported to prolong life in myocardial infarction survivors. These fatty acids can decrease serum triglyceride concentrations, but so far the doses used in trials examining their effects on coronary end points have had only minimal triglyceride lowering effects. OBJECTIVE: To examine the triglyceride lowering effectiveness, safety, and tolerability of Omacor, a concentrate of omega-3, long chain, polyunsaturated fatty acids from fish oil (84% of the total as opposed to an average of 35% in fish oil) over one year in patients with established coronary heart disease (CHD) and persisting hypertriglyceridaemia, despite receiving simvastatin in doses similar to those employed in the Scandinavian simvastatin survival study. SUBJECTS AND METHODS: 59 patients with CHD, receiving simvastatin 10-40 mg daily with serum triglycerides > 2.3 mmol/l, were randomised to receive Omacor 2 g twice a day or placebo for 24 weeks in a double blind trial. Forty six patients accepted the offer of active treatment for a further 24 weeks in an open phase of the trial. RESULTS: There was a sustained significant decrease in serum triglycerides by 20-30% (p < 0.005) and in very low density lipoprotein (VLDL) cholesterol by 30-40% (p < 0.005) in patients receiving active Omacor at three, six, and 12 months compared either to baseline or placebo. Omacor did not have any deleterious effect on low density or high density lipoprotein cholesterol or on biochemical and haematological safety tests. There was no adverse effect on glycaemic control in patients with diabetes, who showed a decrease in serum triglyceride, which was at least as great as in non-diabetic patients. One patient receiving placebo died of acute myocardial infarction. Three patients withdrew from the trial (two on placebo and one on active treatment). Omacor was generally well tolerated. CONCLUSION: Omacor was found to be a safe and effective means of lowering serum triglycerides over one year in patients with CHD and combined hyperlipidaemia, whose triglycerides remained elevated despite simvastatin treatment.
Authors:
P N Durrington; D Bhatnagar; M I Mackness; J Morgan; K Julier; M A Khan; M France
Related Documents :
18426377 - Increased adherence to cardiac standards of care during participation in cardiac diseas...
9712327 - A tale of two trials: the west of scotland coronary prevention study and the texas coro...
15297707 - Progression of coronary atherosclerosis relates to the onset of myocardial infarction i...
12921987 - Antibodies to human heat shock protein 60, hypertension and dyslipidemia. a study of jo...
9822177 - Methods of assessment and clinical relevance of myocardial hibernation and stunning. as...
2182307 - Gissi trials in acute myocardial infarction. rationale, design, and results.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Heart (British Cardiac Society)     Volume:  85     ISSN:  1468-201X     ISO Abbreviation:  Heart     Publication Date:  2001 May 
Date Detail:
Created Date:  2001-04-16     Completed Date:  2001-06-21     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  9602087     Medline TA:  Heart     Country:  England    
Other Details:
Languages:  eng     Pagination:  544-8     Citation Subset:  IM    
Affiliation:
University Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK. pdurrington@hq.cmht.nwest.nhs.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antilipemic Agents / therapeutic use*
Cholesterol / blood
Coronary Disease / blood,  complications,  drug therapy*
Docosahexaenoic Acids / therapeutic use*
Double-Blind Method
Drug Combinations
Drug Therapy, Combination
Eicosapentaenoic Acid / therapeutic use*
Female
Humans
Hypertriglyceridemia / blood,  complications,  drug therapy*
Lipoproteins / blood
Male
Middle Aged
Simvastatin / therapeutic use*
Triglycerides / blood
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 0/Drug Combinations; 0/Lipoproteins; 0/Omacor; 0/Triglycerides; 1553-41-9/Eicosapentaenoic Acid; 25167-62-8/Docosahexaenoic Acids; 57-88-5/Cholesterol; 79902-63-9/Simvastatin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cost effectiveness of ramipril treatment for cardiovascular risk reduction.
Next Document:  Effect of power Doppler and digital subtraction techniques on the comparison of myocardial contrast ...